Accuronix targets sigma-2 receptor for cancer
Accuronix Therapeutics is a leader in discovering and developing a new class of drugs that work by selectively targeting the σ-2 (sigma-2) receptor on cancer cells to deliver cytotoxic payloads. The Accuronix team has established an innovative platform and a lead drug candidate based on advances in characterizing the molecular-targeted drug conjugate (MTDC) approach to cancer therapy. The σ-2 receptors are highly expressed on the surface of rapidly proliferating cancer cells. They internalize upon ligand binding, allowing the delivery of therapeutic agents to intracellular targets. The result is a chemotherapeutic with increased effectiveness and reduction in toxicity risk.
In January 2016, Accuronix licensed our σ-2-based technology from Washington University in St. Louis and assembled a team of experienced biotech scientists and executives, the technology originators, and key executional partners. Accuronix’s σ-2 platform enables the discovery of selective molecularly targeted drug conjugates for a variety of therapeutic cargoes to treat a range of cancers. We are working to advance the development of the lead candidate, ACXT-3102 for pancreatic adenocarcinoma and other rare tumor types; and to progress next-generation MTDCs into development for other oncology indications. The company has raised 1.2 million dollars in local financing and, with the support of the National Cancer Institute, is currently in the process of preparing our lead candidate for IND approval.